Angiotensin converting enzyme inhibition and vascular hypertrophy in hypertension
- PMID: 2285616
- DOI: 10.1007/BF01857638
Angiotensin converting enzyme inhibition and vascular hypertrophy in hypertension
Abstract
The pathogenesis of hypertension is associated with a remodeling of vascular structure. Follow has postulated that the decreased luminal area and thickened medial layer in hypertensive vessels enhances the vasoconstrictive response to vasoactive agents. It is hypothesized that this increase in vascular reactivity may serve to perpetuate hypertension. A growing body of evidence suggests that autocrine-paracrine vasoactive substances and growth factors modulate vascular structure in hypertension. We speculate that therapeutic interventions that normalize blood pressure as well as reverse the vascular remodeling process may have special clinical value. The role of the paracrine renin-angiotensin system and angiotensin converting enzyme inhibitors in hypertension is discussed in this context.
Similar articles
-
Angiotensin-converting enzyme inhibition and vascular structure in hypertension.J Cardiovasc Pharmacol. 1991;18 Suppl 7:S19-24. J Cardiovasc Pharmacol. 1991. PMID: 1725196 Review.
-
Vascular hypertrophy in hypertension: role of the renin-angiotensin system.Mt Sinai J Med. 1998 Mar;65(2):108-17. Mt Sinai J Med. 1998. PMID: 9520514 Review.
-
Reversal of structural changes in hypertensive arteries--a major prospect for the future.S Afr Med J. 1991 Sep 21;Suppl:4-6. S Afr Med J. 1991. PMID: 1925814 Review.
-
Vascular remodeling: the role of angiotensin-converting enzyme inhibitors.Am Heart J. 1998 Feb;135(2 Pt 2):S21-30. doi: 10.1053/hj.1998.v135.86971. Am Heart J. 1998. PMID: 9488609 Review.
-
Effects of angiotensin-converting enzyme inhibition on vascular remodeling of resistance vessels in hypertensive patients.Metabolism. 1998 Dec;47(12 Suppl 1):20-3. doi: 10.1016/s0026-0495(98)90366-3. Metabolism. 1998. PMID: 9867066 Review.
Cited by
-
Dynamics of Vascular Remodeling: An Overview and Bibliography.J Thromb Thrombolysis. 1996;3(1):71-86. doi: 10.1007/BF00226415. J Thromb Thrombolysis. 1996. PMID: 10608041 No abstract available.
-
Endothelial control of vascular and myocardial function in heart failure.Cardiovasc Drugs Ther. 1994 Jun;8(3):437-46. doi: 10.1007/BF00877920. Cardiovasc Drugs Ther. 1994. PMID: 7947359 Review.
-
Angiotensin converting enzyme inhibitors in angina and myocardial infarction. What role will they play in the 1990s?Drugs. 1993 Aug;46(2):209-18. doi: 10.2165/00003495-199346020-00001. Drugs. 1993. PMID: 7691512 Review. No abstract available.
-
Angiotensin II induces delayed mitogenesis and cellular proliferation in rat aortic smooth muscle cells. Correlation with the expression of specific endogenous growth factors and reversal by suramin.J Clin Invest. 1994 Feb;93(2):788-98. doi: 10.1172/JCI117033. J Clin Invest. 1994. PMID: 7509348 Free PMC article.
-
The renin-angiotensin system and coronary vasomotion.Heart. 1996 Nov;76(3 Suppl 3):45-52. doi: 10.1136/hrt.76.3_suppl_3.45. Heart. 1996. PMID: 8977364 Free PMC article. Review. No abstract available.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Medical